

## Clinical Policy: Sirolimus Protein-Bound Particles (Fyarro)

Reference Number: LA.PHAR.574

Effective Date:

Last Review Date: 05.01.23

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Sirolimus protein-bound particles (Fyarro™) is a mammalian target of rapamycin (mTOR) inhibitors.

### FDA Approved Indication(s)

Fyarro is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections® that Fyarro is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Perivascular Epithelioid Cell Tumor (PEComa) (must meet all):

1. Diagnosis of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa);
2. Request is for Fyarro;
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years;
5. Use as a single agent;
6. Member does not have PEComa type lymphangioleiomyomatosis;
7. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 100 mg/m<sup>2</sup> IV on Days 1 and 8 of each 21 day cycle;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:** 6 months

##### B. Other diagnoses/indications (must meet 1 or 2):

- a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255

## CLINICAL POLICY

### Sirolimus

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Perivascular Epithelioid Cell Tumor (PEComa) (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Fyarro for a covered indication and has received this medication for at least 30 days;
2. Request is for Fyarro;
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. Both of the following (i and ii):
    - i. New dose does not exceed 100 mg/m<sup>2</sup> IV on Days 1 and 8 of each 21 day cycle;
    - ii. Dose is at least 45 mg/m<sup>2</sup> IV on Days 1 and 8 of each 21 day cycle;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:** 12 months

### B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

## III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid or evidence of coverage documents.

## IV. Appendices/General Information

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

NCCN: National Comprehensive Cancer Network

PEComa: perivascular epithelioid cell tumor

*Appendix B: Therapeutic Alternatives*

## CLINICAL POLICY

### Sirolimus

Not Applicable

#### *Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): History of severe hypersensitivity to sirolimus, other rapamycin derivatives, or albumin.
- Boxed warning(s): None reported

#### V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Sirolimus protein-bound particles (Fyarro)	Locally advanced unresectable or metastatic malignant PEComa	100 mg/m <sup>2</sup> administered as an IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity	100 mg/m <sup>2</sup> administered as an IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle

#### VI. Product Availability

Drug Name	Availability
Sirolimus protein-bound particles (Fyarro)	Lyophilized powder for infusion: 100 mg of sirolimus formulated as albumin-bound particles in single-dose vial for reconstitution

#### VII. References

1. Fyarro Prescribing Information. Pacific Palisades, CA. Aadi Bioscience, Inc; November 2021. Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/213312Orig1s000Corrected\\_lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213312Orig1s000Corrected_lbl.pdf). Accessed November 3, 2022.
2. National Comprehensive Cancer Network. Soft Tissue Sarcoma Version 2.2022. Available at [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf). Accessed November 3, 2022.
3. ClinicalTrials.gov. A Phase 2 Study of ABI-009 in Patients with Advanced Malignant PEComa (AMPECT). Available at <https://www.clinicaltrials.gov/ct2/show/NCT02494570>. Accessed November 3, 2022.
4. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for Angiomyolipoma in Tuberous Sclerosis complex or Lymphangioleiomyomatosis. The New England Journal of Medicine. 2008; 358:140-51.
5. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical Activity of mTOR Inhibition with Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology. 2010; DOI: 10.1200/JCO.2009.25.2981.

## CLINICAL POLICY

### Sirolimus

6. Wataya-Kaneda M, Ohno Y, Fujita Y, et al. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial. *JAMA Dermatol.* 2018 Jul 1;154(7):781-788.
7. Northrup H, Aronow ME, Bebin EM, et al. International Tuberous Sclerosis Complex Consensus Group. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. *Pediatr Neurol.* 2021 Oct;123:50-66.

### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9331	Injection, sirolimus protein-bound particles (Fyarro), 1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created.	05.01.23	

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between

## CLINICAL POLICY

### Sirolimus

the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.